



The formula has been successful in animal trials, and is now being tested on humans | Photo source [Pixabay](#)

[Innovation](#) > [Health & Wellbeing](#) > [French biotech firm develops long-lasting flu vaccine](#)

FRENCH BIOTECH FIRM DEVELOPS LONG-LASTING FLU VACCINE

 HEALTH & WELLBEING

Osivax is seeking to prevent influenza outbreaks by targeting a specific part of the virus

Spotted: French-based [Osivax](#) is developing a universal flu vaccination designed to prevent various strains of the influenza virus for years. The vaccination will be more effective than current flu shots and [will not need to be renewed annually](#).

“Currently available seasonal flu vaccines are limited in addressing all flu strains because they target highly variable regions of the virus,” said [Alexandre Le Vert](#), CEO and co-founder of [Osivax](#).

Osivax’s lead candidate version, OVX836, targets a particular part of the virus, the NucleoProtein. By targeting the NucleoProtein, it should stay effective even as the virus mutates. The formula has been [successful in animal trials](#) and is now being tested on humans.

18th July 2019

Email: contact@osivax.com

Website: www.osivax.com

Contact: osivax.com/contact

Takeaway:

Influenza kills about 290,000 to 650,000 people a year. Osivax is one of many companies looking for ways to prevent this. The company's research has already gained investor interests. The company recently raised 8 million euro to work on a second-generation vaccination for A and B influenza strains. Springwise has spotted other efforts to prevent influenza and other viruses. A Swedish manufacturer has created a scarf that protects its wearer from air-borne germs. A Japanese company has developed a quick and inexpensive test for infectious diseases.